Biodesix Closes on $20M in Structured Debt Financing | GenomeWeb

Biodesix said this week that it has closed a structured debt financing with Capital Royalty Partners that provides the company with up to $20 million.

The funds will be used for ongoing development of Biodesix's technology platform and expansion of sales and marketing efforts in support of its VeriStrat proteomic test for guiding therapy in non-small cell lung cancer, the company said.

The deal follows the close by Biodesix in January of a $14.4 million Series E funding round.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.